Pavan Rawat
@pavan.rawat.6715
Indore
5+ Years of experience
SEBI Registration INH000025966
Trade Ideas
163
Opinions
133
Followers
1k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 1 hour ago
HAL TO DELIVER FIRST BATCH OF HTT-40 TRAINER AIRCRAFT TO IAF
HAL
Hindustan Aeronautics Ltd. is set to deliver the first batch of HTT-40 basic trainer aircraft to the Indian Air Force (IAF), helping address the force’s growing requirement for pilot training. Three HTT-40 (Hindustan Turbo Trainer-40) aircraft are reportedly ready for delivery—two manufactured at HAL’s Bengaluru facility and one at Nashik, officials familiar with the development told the newspaper.
The IAF placed an order for 70 HTT-40 aircraft worth ₹6,838 crore with HAL in 2023 for training rookie pilots. HAL was scheduled to deliver 12 aircraft during 2025-26, but deliveries were delayed due to a shortage of engines. The delay was attributed to supply-chain challenges faced by Honeywell, the US-based company that supplies TPE331-12B turboprop engines for the aircraft. Honeywell delivered its first batch of engines a few months ago and has assured HAL of timely supplies going forward.
Defence Minister Rajnath Singh inaugurated HTT-40 and LCA-Mk1A production lines at HAL’s Nashik facility in October last year. With the new production lines, HAL has the capacity to manufacture up to 20 HTT-40 aircraft annually across its Bengaluru and Nashik facilities. Currently, all IAF rookie pilots undergo Stage-I or ab initio flying training on Swiss-origin Pilatus PC-7 MkII basic trainer aircraft. After completing this common training stage, pilots are divided into fighter, transport and helicopter streams. Fighter pilots then undergo Stage-II training on the PC-7 MkII and Kiran Mk-1A jet trainers, followed by Stage-III training on British-origin Hawk advanced jet trainers. shared an insight ⚡️ 18 hours ago
PVR INOX FALL AMID INTERNAL PROBE INTO ALLEGED
PVRINOX
PVR INOX shares fell nearly 8% on September 7 after a report by The Economic Times said the multiplex operator had asked a senior executive to leave in April following an internal investigation into alleged kickbacks linked to developers involved in building its cinema properties. According to the report, Pramod Arora, PVR INOX’s Chief Executive Officer for Growth and Investment, was allegedly involved in receiving kickbacks from developers of cinema properties.
Arora had played a key role in PVR INOX’s expansion into Tier-II and Tier-III cities, particularly through asset-light formats. These included franchise-owned, company-operated cinemas as well as the SMART/Smart Screen initiatives, which were aimed at offering lower-cost, digital-first multiplexes in smaller cities and towns. The company reportedly became aware of the allegations in April, following which Arora and a few other employees were asked to leave with immediate effect.
The report further stated that a declaration signed by Arora restricted him from joining rival cinema chains and approaching PVR INOX’s existing vendors. The document also reportedly allows the company to pursue legal action if these restrictions are breached. Meanwhile, PVR INOX’s board approved a ₹300 crore share buyback on August 31, 2026. Under the proposal, the company will repurchase up to 20,68,965 equity shares at ₹1,450 per share, representing an approximately 20% premium to the August 31 closing price. The buyback will be conducted through the tender offer route via the stock exchange mechanism and represents around 2.11% of the company’s total paid-up equity capital. shared an insight ⚡️ 21 hours ago
LUPIN IN FOCUS POST MODAFINIL TABLETS APPROVAL FROM USFDA
LUPIN
Lupin shares are likely to remain in focus on September 7 after the pharmaceutical company received approval from the United States Food and Drug Administration (USFDA) for its generic drug used to improve wakefulness in adults with excessive sleepiness. The company announced that it received USFDA approval for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg.
The approved tablets have been determined to be bioequivalent to the reference listed drug (RLD), Provigil Tablets, marketed by Nuvo Pharmaceuticals (Ireland) DAC. Modafinil is indicated to improve wakefulness in adult patients experiencing excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).
In August, Lupin's subsidiary VISUfarma B.V. entered into an exclusive licensing agreement with Visus Therapeutics, a subsidiary of Tenpoint Therapeutics, to commercialise, market, promote, distribute and sell YUVEZZI. Lupin shares touched a 52-week high of ₹2,530, and a 52-week low of ₹1,900.30. The stock is currently trading 16.56% below its 52-week high and 11.09% above its 52-week low. The company's market capitalisation stands at approximately ₹96,528.82 crore.FAQ's
What are the top stock recommendations by Pavan Rawat?
Pavan Rawat regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Jindal Worldwide Ltd (Bullish), HAL, PVRINOX and LUPIN. Explore Pavan Rawat's complete list of posts and trade views on their StockGro profile.
How can I follow Pavan Rawat's latest investment insights?
You can follow Pavan Rawat's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Pavan Rawat's investment strategy?
Pavan Rawat follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Pavan Rawat been a SEBI-registered Research Analyst (RA)?
Pavan Rawat has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Pavan Rawat's past performance and stock picks?
You can check Pavan Rawat's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Pavan Rawat for stock market advice?
For stock market guidance from Pavan Rawat, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Pavan Rawat's track record in predicting market movements?
Pavan Rawat has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Pavan Rawat?
Pavan Rawat is a SEBI-registered Research Analyst with the SEBI Registration INH000025966. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro